Neoadjuvant immunochemotherapy vs. neoadjuvant targeted therapy plus chemotherapy for EGFR-mutated non-small cell lung cancer: a retrospective study.
1/5 보강
PICO 자동 추출 (휴리스틱, conf 3/4)
유사 논문P · Population 대상 환자/모집단
89 patients (53 females, 36 males) with a median age of 57 (Interquartile range [IQR], 51–57) years.
I · Intervention 중재 / 시술
surgery following NICT or NTCT
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
The 1-year DFS rates were 0.872 (95%CI, 0.762–0.998) in the NICT group and 0.721 (95%CI, 0.586–0.887) in the NTCT group ( = 0.18). [CONCLUSIONS] NICT seemed to be an effective treatment for patients with EGFR-mutated NSCLC, further randomized controlled trials are in need to validate the safety and efficacy of NICT in this setting.
[BACKGROUND] Adjuvant targeted therapy represents the standard of care for patients with resectable epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC).
- 95% CI 6.5–29.5
APA
Li F, Zhang C, et al. (2026). Neoadjuvant immunochemotherapy vs. neoadjuvant targeted therapy plus chemotherapy for EGFR-mutated non-small cell lung cancer: a retrospective study.. BMC cancer, 26(1), 247. https://doi.org/10.1186/s12885-026-15582-6
MLA
Li F, et al.. "Neoadjuvant immunochemotherapy vs. neoadjuvant targeted therapy plus chemotherapy for EGFR-mutated non-small cell lung cancer: a retrospective study.." BMC cancer, vol. 26, no. 1, 2026, pp. 247.
PMID
41559619 ↗
Abstract 한글 요약
[BACKGROUND] Adjuvant targeted therapy represents the standard of care for patients with resectable epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC). Neoadjuvant therapy can improve surgical and survival outcomes. This study aimed to compare the effectiveness of neoadjuvant immunochemotherapy (NICT) and neoadjuvant targeted therapy plus chemotherapy (NTCT) for EGFR-mutated NSCLCs.
[METHODS] In this multi-center retrospective study, we reviewed patients with EGFR-mutated NSCLC who underwent surgery following NICT or NTCT. The primary end point was major pathologic response (MPR), and the secondary end points included pathologic complete response (pCR) and 1-year disease-free survival (DFS).
[RESULTS] This study included 89 patients (53 females, 36 males) with a median age of 57 (Interquartile range [IQR], 51–57) years. Of these, there were 44 and 45 patients undergoing surgery following NICT and NTCT respectively. Patients who received NICT had a more advanced clinical T stage ( = 0.018), a higher frequency of harboring EGFR exon 20 insertion ( = 0.035) and a shorter length of hospital stay ( = 0.005), compared with those who received NTCT. The MPR rate was 29.5% (95% confidence interval [CI], 16.8–45.2) in the NICT group, compared with 15.6% (95%CI, 6.5–29.5) in the NTCT group ( = 0.185). The 1-year DFS rates were 0.872 (95%CI, 0.762–0.998) in the NICT group and 0.721 (95%CI, 0.586–0.887) in the NTCT group ( = 0.18).
[CONCLUSIONS] NICT seemed to be an effective treatment for patients with EGFR-mutated NSCLC, further randomized controlled trials are in need to validate the safety and efficacy of NICT in this setting.
[METHODS] In this multi-center retrospective study, we reviewed patients with EGFR-mutated NSCLC who underwent surgery following NICT or NTCT. The primary end point was major pathologic response (MPR), and the secondary end points included pathologic complete response (pCR) and 1-year disease-free survival (DFS).
[RESULTS] This study included 89 patients (53 females, 36 males) with a median age of 57 (Interquartile range [IQR], 51–57) years. Of these, there were 44 and 45 patients undergoing surgery following NICT and NTCT respectively. Patients who received NICT had a more advanced clinical T stage ( = 0.018), a higher frequency of harboring EGFR exon 20 insertion ( = 0.035) and a shorter length of hospital stay ( = 0.005), compared with those who received NTCT. The MPR rate was 29.5% (95% confidence interval [CI], 16.8–45.2) in the NICT group, compared with 15.6% (95%CI, 6.5–29.5) in the NTCT group ( = 0.185). The 1-year DFS rates were 0.872 (95%CI, 0.762–0.998) in the NICT group and 0.721 (95%CI, 0.586–0.887) in the NTCT group ( = 0.18).
[CONCLUSIONS] NICT seemed to be an effective treatment for patients with EGFR-mutated NSCLC, further randomized controlled trials are in need to validate the safety and efficacy of NICT in this setting.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (5)
- Infection Misdiagnosed as Lung Cancer and Retrospective Literature Analysis.
- PELI3-Mediating Epithelial-Mesenchymal Transition Correlates with Radiation Sensitivity in Non-Small Cell Lung Cancer.
- Malignant hepatic perivascular epithelioid cell tumor: A case report and literature review.
- Simultaneous activation of apoptosis and cGAS-STING pathway with a mitochondria-targeted dehydrocholic acid compound for enhanced hepatocellular carcinoma chemoimmunotherapy.
- Obesity, chronic breast inflammation and carcinogenesis: Molecular pathways and clinical implications (Review).
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Unleashing CAR-T potential in solid tumors: overcoming intrinsic and extrinsic hurdles to improve therapy.
- Novel roles of SETD2 in tumor metabolism and immunotherapy: a systematic review and meta-analysis.
- Negative trial but positive lesson: reframing immunotherapy resistance from one-size-fits-all to precision strategies.
- SLC2A1 tumour-associated macrophages spatially control CD8 T cell function and drive resistance to immunotherapy in non-small-cell lung cancer.
- Chalcone-containing dual-targeting PD-L1/tubulin small molecules: a novel approach for cancer immunotherapy.
- Copper-enriched zinc peroxides induced cuproptosis through concurrent metabolic and oxidative dysregulation for boosting immunotherapy in colorectal cancer.